Clinical Trials

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT06027086 2026-02-12

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

27 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

196 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Hepatocellular

NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

34 enrolled

Adenocarcinoma Of Esophagus

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

39 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT04781192 2026-01-23

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

40 enrolled

Advanced Biliary Tract Cancer

NCT03539822 2026-01-21

CAMILLA

117 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

25 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

50 enrolled

Biliary Tract Neoplasms

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

32 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

10 enrolled

Carcinoma, Hepatocellular

NCT06546969 2025-12-10

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

15 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Phase 1 Active not recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03257761 2025-12-05

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

55 enrolled

Phase 2 Active not recruiting

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

50 enrolled

Cholangiocarcinoma

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

25 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT06440993 2025-12-01

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

42 enrolled

BreastDermatologicGastrointestinalThoracic

Cholangiocarcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03777813 2025-11-18

ARION

Phase 2 Completed

112 enrolled

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07226063 2025-11-10

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

16 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06698250 2025-11-06

ZENOBIA

40 enrolled

Carcinoma, Hepatocellular

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

16 enrolled

Phase 1/2 Active not recruiting

Cholangiocarcinoma

NCT03245541 2025-10-07

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

18 enrolled

Pancreatic Adenocarcinoma

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04257448 2025-09-30

SEPION

Phase 1/2 Completed

75 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

45 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT02962063 2025-09-05

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

64 enrolled

Phase 2 Active not recruiting

Adenocarcinoma Of Esophagus

NCT05194293 2025-09-04

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

4 enrolled